Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis
Vasiliki Koliaraki, Manolis Roulis, George Kollias
Vasiliki Koliaraki, Manolis Roulis, George Kollias
View: Text | PDF
Research Article Oncology

Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis

  • Text
  • PDF
Abstract

The tumor microenvironment plays a significant role in colitis-associated cancer (CAC). Intestinal myofibroblasts (IMFs) are cells in the intestinal lamina propria secreting factors that are known to modulate carcinogenesis; however, the physiological role of IMFs and signaling pathways influencing CAC have remained unknown. Tumor progression locus 2 (Tpl2) is a MAPK that regulates inflammatory and oncogenic pathways. In this study we addressed the role of Tpl2 in CAC using complete and tissue-specific ablation of Tpl2 in mutant mice. Tpl2-deficient mice did not exhibit significant differences in inflammatory burdens following azoxymethane (AOM)/dextran sodium sulfate (DSS) administration compared with wild-type mice; however, the mutant mice developed significantly increased numbers and sizes of tumors, associated with enhanced epithelial proliferation and decreased apoptosis. Cell-specific ablation of Tpl2 in IMFs, but not in intestinal epithelial or myeloid cells, conferred a similar susceptibility to adenocarcinoma formation. Tpl2-deficient IMFs upregulated HGF production and became less sensitive to the negative regulation of HGF by TGF-β3. In vivo inhibition of HGF-mediated c-Met activation blocked early, enhanced colon dysplasia in Tpl2-deficient mice, indicating that Tpl2 normally suppresses the HGF/c-Met pathway. These findings establish a mesenchyme-specific role for Tpl2 in the regulation of HGF production and suppression of epithelial tumorigenesis.

Authors

Vasiliki Koliaraki, Manolis Roulis, George Kollias

×

Figure 5

Tpl2 ablation results in increased HGF expression in IMFs and subsequent activation of the c-Met signaling pathway in IECs.

Options: View larger image (or click on image) Download as PowerPoint
Tpl2 ablation results in increased HGF expression in IMFs and subsequent...
(A) Hgf gene expression levels in colons from wild-type and Tpl2D/D mice on days 0 and 8 of the AOM/DSS experimental protocol. Gene expression was normalized to B2m levels. Data represent mean ± SEM of 6 mice per genotype (2 mice from each of 3 individual experiments). **P < 0.01. (B) Western blot analysis of colon lysates from the same mice for p-Met and p-Akt. β-Actin was used as a loading control. This experiment represents one of 3. (C) HGF gene expression levels in colons from Tpl2fl/fl and Tpl2IMFko mice on days 0 and 15 after initial injection with AOM. Gene expression was normalized to B2m levels. Data represent mean ± SEM of 6 mice per genotype (2 mice from each of 3 individual experiments). *P < 0.05, **P < 0.01. (D) Western blot analysis of colon lysates from the same mice for p-Met and p-Akt. β-Actin was used as a loading control. This experiment represents one of 3 performed. (E) Western blot analysis from epithelial cells (IECs) and stroma, isolated from wild-type and Tpl2D/D mice, on days 0 and 8 of the AOM/DSS experimental protocol. β-Actin was used as a loading control. This experiment represents one of 3 performed. (F) Hgf gene expression levels in epithelial cells (IECs) and stroma, isolated from wild-type and Tpl2D/D mice on day 8 of the AOM/DSS experimental protocol. Gene expression was normalized to B2m levels. Data represent mean ± SEM of 6 mice per genotype (3 mice from each of 2 individual experiments).**P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts